Literature DB >> 29925726

Methotrexate-associated lymphoproliferative disorder complicated by severe acute respiratory failure and ileal perforation:a case report.

Eiji Suzuki1, Takashi Kanno1, Satoru Kimura2, Takumi Irie3, Hajime Odajima4, Kiyoshi Migita5.   

Abstract

Lymphoproliferative disorder (LPD) is a potentially severe adverse effect of methotrexate (MTX) administration in patients with rheumatoid arthritis (RA). We report a case of MTX-associated LPD (MTX-LPD) in a patient with RA who developed severe pulmonary failure complicated by perforation of the terminal ileum. A 61-year-old woman with RA receiving MTX complained of dyspnea and abdominal pain. She was diagnosed with intestinal perforation and peritonitis, and underwent immediate abdominal surgery. Pathological examinations of the specimen obtained from the resected ileum and a bone marrow aspirate revealed diffuse large B-cell lymphoma. Steroid therapy failed to improve her respiratory failure, but her condition improved after abdominal surgery and suspension of MTX. MTX-LPD can result in multiple life-threatening conditions; however, the symptoms are highly variable. RA patients receiving MTX should thus be monitored carefully, and MTX administration should be stopped immediately on suspicion of MTX-LPD.

Entities:  

Keywords:  intestinal perforation; methotrexate; methotrexate-associated lymphoproliferative disorder; respiratory failure; rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 29925726      PMCID: PMC6141454          DOI: 10.5387/fms.2017-23

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  17 in total

1.  Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.

Authors:  Yoshihiko Hoshida; Jing-Xian Xu; Shigeki Fujita; Itsuko Nakamichi; Jun-Ichiro Ikeda; Yasuhiko Tomita; Shin-Ichi Nakatsuka; Jun-Ichi Tamaru; Atsushi Iizuka; Tsutomu Takeuchi; Katsuyuki Aozasa
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

2.  Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis.

Authors:  O W Kamel; M van de Rijn; L M Weiss; G J Del Zoppo; P K Hench; B A Robbins; P G Montgomery; R A Warnke; R F Dorfman
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

3.  Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression.

Authors:  Michihide Tokuhira; Shuntaro Saito; Ayumi Okuyama; Katsuya Suzuki; Morihiro Higashi; Shuji Momose; Takayuki Shimizu; Takehiko Mori; Tomoe Anan-Nemoto; Koichi Amano; Shinichiro Okamoto; Tsutomu Takeuchi; Jun-Ichi Tamaru; Masahiro Kizaki
Journal:  Leuk Lymphoma       Date:  2017-09-07

4.  Bowel perforation in intestinal lymphoma: incidence and clinical features.

Authors:  R Vaidya; T M Habermann; J H Donohue; K M Ristow; M J Maurer; W R Macon; J P Colgan; D J Inwards; S M Ansell; L F Porrata; I N Micallef; P B Johnston; S N Markovic; C A Thompson; G S Nowakowski; T E Witzig
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

Review 5.  Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature.

Authors:  Rita Rizzi; Paola Curci; Mario Delia; Erminia Rinaldi; Antonia Chiefa; Giorgina Specchia; Vincenzo Liso
Journal:  Med Oncol       Date:  2008-05-07       Impact factor: 3.064

6.  Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.

Authors:  Ayako Ichikawa; Fumiko Arakawa; Junichi Kiyasu; Kensaku Sato; Hiroaki Miyoshi; Daisuke Niino; Yoshizo Kimura; Masanori Takeuchi; Maki Yoshida; Yukinao Ishibashi; Shinji Nakashima; Yasuo Sugita; Osamu Miura; Koichi Ohshima
Journal:  Eur J Haematol       Date:  2013-05-13       Impact factor: 2.997

7.  Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.

Authors:  Satoshi Takanashi; Yoshinobu Aisa; Chisako Ito; Hideki Arakaki; Yuki Osada; Yuichiro Amano; Motoharu Hirano; Tomonori Nakazato
Journal:  Rheumatol Int       Date:  2017-07-05       Impact factor: 2.631

Review 8.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Rheumatol       Date:  2015-11-06       Impact factor: 10.995

Review 9.  [A case of rheumatoid arthritis with malignant lymphoma taking methotrexate].

Authors:  M Hayakawa; T Morita
Journal:  Ryumachi       Date:  1995-08

Review 10.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Authors:  Josef S Smolen; Robert Landewé; Johannes Bijlsma; Gerd Burmester; Katerina Chatzidionysiou; Maxime Dougados; Jackie Nam; Sofia Ramiro; Marieke Voshaar; Ronald van Vollenhoven; Daniel Aletaha; Martin Aringer; Maarten Boers; Chris D Buckley; Frank Buttgereit; Vivian Bykerk; Mario Cardiel; Bernard Combe; Maurizio Cutolo; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Cem Gabay; Juan Gomez-Reino; Laure Gossec; Jacques-Eric Gottenberg; Johanna M W Hazes; Tom Huizinga; Meghna Jani; Dmitry Karateev; Marios Kouloumas; Tore Kvien; Zhanguo Li; Xavier Mariette; Iain McInnes; Eduardo Mysler; Peter Nash; Karel Pavelka; Gyula Poór; Christophe Richez; Piet van Riel; Andrea Rubbert-Roth; Kenneth Saag; Jose da Silva; Tanja Stamm; Tsutomu Takeuchi; René Westhovens; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-03-06       Impact factor: 19.103

View more
  2 in total

1.  Mesenchymal Stem Cells Enhance Therapeutic Effect and Prevent Adverse Gastrointestinal Reaction of Methotrexate Treatment in Collagen-Induced Arthritis.

Authors:  Qiming Zhai; Jiayi Dong; Xuesi Zhang; Xiaoning He; Dongdong Fei; Yan Jin; Bei Li; Fang Jin
Journal:  Stem Cells Int       Date:  2021-01-09       Impact factor: 5.443

2.  Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report.

Authors:  Masahiro Nomura; Ryusuke Sumiya; Hayato Ono; Takeshi Nagai; Keigo Kumazawa; Atsushi Shimizu; Daisuke Endo; Nobuyoshi Aoyanagi
Journal:  World J Surg Oncol       Date:  2021-01-02       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.